5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Tumor O
lysis O
syndrome O
: O
Administer O
aggressive O
intravenous O
hydration O
, O
anti-hyperuricemic O
agents O
, O
monitor O
renal O
function O
( O
5.5 O
) O
. O

* O
Infections O
: O
Withhold O
Rituxan O
and O
institute O
appropriate O
anti-infective O
therapy O
( O
5.6 O
) O
. O

* O
Cardiac O
arrhythmias O
and O
angina O
: O
Discontinue O
infusions O
in O
case O
of O
serious O
or O
life-threatening O
events O
( O
5.7 O
) O
. O

* O
Bowel O
obstruction O
and O
perforation O
: O
Consider O
and O
evaluate O
for O
abdominal O
pain O
, O
vomiting O
, O
or O
related O
symptoms O
( O
5.9 O
) O
. O

* O
Live O
virus O
vaccines O
: O
Do O
not O
administer O
live O
virus O
vaccines O
prior O
to O
or O
during O
Rituxan O
( O
5.10 O
) O
. O

* O
Cytopenias O
: O
Monitor O
blood O
counts O
at O
regular O
intervals O
( O
5.11 O
, O
6.1 O
) O
. O

5.1 O
Infusion O
Reactions O
Rituxan O
can O
cause O
severe O
, O
including O
fatal B-NonOSE_AE
, O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Severe O
reactions O
typically O
occurred O
during O
the O
first O
infusion O
with O
time O
to O
onset O
of O
30-120 O
minutes O
. O

Rituxan B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
infusion I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
sequelae O
include O
urticaria B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
angioedema B-NonOSE_AE
, O
hypoxia B-NonOSE_AE
, O
bronchospasm B-NonOSE_AE
, O
pulmonary B-NonOSE_AE
infiltrates I-NonOSE_AE
, O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
distress I-NonOSE_AE
syndrome I-NonOSE_AE
, O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
ventricular B-NonOSE_AE
fibrillation I-NonOSE_AE
, O
cardiogenic B-NonOSE_AE
shock I-NonOSE_AE
, O
anaphylactoid B-NonOSE_AE
events I-NonOSE_AE
, O
or O
death B-NonOSE_AE
. O

Premedicate O
patients O
with O
an O
antihistamine O
and O
acetaminophen O
prior O
to O
dosing O
. O

For O
RA B-Not_AE_Candidate
patients O
, O
methylprednisolone O
100 O
mg O
intravenously O
or O
its O
equivalent O
is O
recommended O
30 O
minutes O
prior O
to O
each O
infusion O
. O

Institute O
medical O
management O
( O
e.g O
. O

glucocorticoids O
, O
epinephrine O
, O
bronchodilators O
, O
or O
oxygen O
) O
for O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
as O
needed O
. O

Depending O
on O
the O
severity O
of O
the O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
and O
the O
required O
interventions O
, O
temporarily O
or O
permanently O
discontinue O
Rituxan O
. O

Resume O
infusion O
at O
a O
minimum O
50 O
% O
reduction O
in O
rate O
after O
symptoms O
have O
resolved O
. O

Closely O
monitor O
the O
following O
patients O
: O
those O
with O
pre-existing O
cardiac B-Not_AE_Candidate
or O
pulmonary O
conditions I-Not_AE_Candidate
, O
those O
who O
experienced O
prior O
cardiopulmonary B-Not_AE_Candidate
adverse I-Not_AE_Candidate
reactions I-Not_AE_Candidate
, O
and O
those O
with O
high B-Not_AE_Candidate
numbers I-Not_AE_Candidate
of I-Not_AE_Candidate
circulating I-Not_AE_Candidate
malignant I-Not_AE_Candidate
cells I-Not_AE_Candidate
( I-Not_AE_Candidate
> I-Not_AE_Candidate
= I-Not_AE_Candidate
2 I-Not_AE_Candidate
5 I-Not_AE_Candidate
, I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
) O
. O

[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.7 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.2 O
Severe O
Mucocutaneous O
Reactions O
Mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
some O
with O
fatal B-NonOSE_AE
outcome O
, O
can O
occur O
in O
patients O
treated O
with O
Rituxan O
. O

These O
reactions O
include O
paraneoplastic B-OSE_Labeled_AE
pemphigus I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
lichenoid B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
vesiculobullous B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
. O

The O
onset O
of O
these O
reactions O
has O
been O
variable O
and O
includes O
reports O
with O
onset O
on O
the O
first O
day O
of O
Rituxan O
exposure O
. O

Discontinue O
Rituxan O
in O
patients O
who O
experience O
a O
severe O
mucocutaneous B-NonOSE_AE
reaction I-NonOSE_AE
. O

The O
safety O
of O
readministration O
of O
Rituxan O
to O
patients O
with O
severe O
mucocutaneous B-NonOSE_AE
reactions I-NonOSE_AE
has O
not O
been O
determined O
. O

[ O
See O
Boxed O
Warning O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.3 O
Hepatitis O
B O
Virus O
Reactivation O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
) I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
in O
some O
cases O
resulting O
in O
fulminant O
hepatitis B-NonOSE_AE
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
and O
death B-NonOSE_AE
, O
can O
occur O
in O
patients O
treated O
with O
drugs O
classified O
as O
CD B-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
- I-NonOSE_AE
directed I-NonOSE_AE
cytolytic I-NonOSE_AE
antibodies I-NonOSE_AE
, O
including O
Rituxan O
. O

Cases O
have O
been O
reported O
in O
patients O
who O
are O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antigen I-Not_AE_Candidate
( I-Not_AE_Candidate
HBsAg I-Not_AE_Candidate
) I-Not_AE_Candidate
positive I-Not_AE_Candidate
and O
also O
in O
patients O
who O
are O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
but O
are O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
core I-Not_AE_Candidate
antibody I-Not_AE_Candidate
( I-Not_AE_Candidate
anti I-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
) I-Not_AE_Candidate
positive I-Not_AE_Candidate
. O

Reactivation O
also O
has O
occurred O
in O
patients O
who O
appear O
to O
have O
resolved O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
( I-Not_AE_Candidate
i I-Not_AE_Candidate
. I-Not_AE_Candidate
e I-Not_AE_Candidate
. I-Not_AE_Candidate
, I-Not_AE_Candidate
HBsAg I-Not_AE_Candidate
negative I-Not_AE_Candidate
, O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
and O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antibody I-Not_AE_Candidate
[ I-Not_AE_Candidate
anti I-Not_AE_Candidate
- I-Not_AE_Candidate
HBs I-Not_AE_Candidate
] I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
. O

HBV B-NonOSE_AE
reactivation I-NonOSE_AE
is O
defined O
as O
an O
abrupt O
increase B-NonOSE_AE
in I-NonOSE_AE
HBV I-NonOSE_AE
replication I-NonOSE_AE
manifesting O
as O
a O
rapid O
increase B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
HBV I-NonOSE_AE
DNA I-NonOSE_AE
level I-NonOSE_AE
or O
detection B-NonOSE_AE
of I-NonOSE_AE
HBsAg I-NonOSE_AE
in O
a O
person O
who O
was O
previously O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
and O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
. O

Reactivation B-NonOSE_AE
of I-NonOSE_AE
HBV I-NonOSE_AE
replication I-NonOSE_AE
is O
often O
followed O
by O
hepatitis B-NonOSE_AE
, O
i.e. O
, O
increase B-NonOSE_AE
in I-NonOSE_AE
transaminase I-NonOSE_AE
levels I-NonOSE_AE
. O

In O
severe O
cases O
increase B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
levels I-NonOSE_AE
, O
liver B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
can O
occur O
. O

Screen O
all O
patients O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
by O
measuring O
HBsAg O
and O
anti-HBc O
before O
initiating O
treatment O
with O
Rituxan O
. O

For O
patients O
who O
show O
evidence O
of O
prior O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
( O
HBsAg B-Not_AE_Candidate
positive I-Not_AE_Candidate
[ O
regardless O
of O
antibody B-NonOSE_AE
status O
] O
or O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
but O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
, O
consult O
with O
physicians O
with O
expertise O
in O
managing O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
regarding O
monitoring O
and O
consideration O
for O
HBV B-NonOSE_AE
antiviral O
therapy O
before O
and/or O
during O
Rituxan O
treatment O
. O

Monitor O
patients O
with O
evidence O
of O
current O
or O
prior O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
for O
clinical O
and O
laboratory O
signs O
of O
hepatitis B-NonOSE_AE
or O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
during O
and O
for O
several O
months O
following O
Rituxan O
therapy O
. O

HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
has O
been O
reported O
up O
to O
24 O
months O
following O
completion O
of O
Rituxan O
therapy O
. O

In O
patients O
who O
develop O
reactivation B-NonOSE_AE
of I-NonOSE_AE
HBV I-NonOSE_AE
while O
on O
Rituxan O
, O
immediately O
discontinue O
Rituxan O
and O
any O
concomitant O
chemotherapy O
, O
and O
institute O
appropriate O
treatment O
. O

Insufficient O
data O
exist O
regarding O
the O
safety O
of O
resuming O
Rituxan O
in O
patients O
who O
develop O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

Resumption O
of O
Rituxan O
in O
patients O
whose O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
resolves O
should O
be O
discussed O
with O
physicians O
with O
expertise O
in O
managing O
hepatitis O
B O
. O

[ O
See O
Boxed O
Warning O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
5.4 O
Progressive B-OSE_Labeled_AE
Multifocal I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
JC B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
resulting O
in O
PML B-OSE_Labeled_AE
and O
death B-NonOSE_AE
can O
occur O
in O
Rituxan-treated O
patients O
with O
hematologic B-Not_AE_Candidate
malignancies I-Not_AE_Candidate
or O
with O
autoimmune B-Not_AE_Candidate
diseases I-Not_AE_Candidate
. O

The O
majority O
of O
patients O
with O
hematologic B-Not_AE_Candidate
malignancies I-Not_AE_Candidate
diagnosed O
with O
PML B-OSE_Labeled_AE
received O
Rituxan O
in O
combination O
with O
chemotherapy O
or O
as O
part O
of O
a O
hematopoietic O
stem O
cell O
transplant O
. O

The O
patients O
with O
autoimmune B-Not_AE_Candidate
diseases I-Not_AE_Candidate
had O
prior O
or O
concurrent O
immunosuppressive O
therapy O
. O

Most O
cases O
of O
PML B-OSE_Labeled_AE
were O
diagnosed O
within O
12 O
months O
of O
their O
last O
infusion O
of O
Rituxan O
. O

Consider O
the O
diagnosis O
of O
PML B-NonOSE_AE
in O
any O
patient O
presenting O
with O
new-onset O
neurologic O
manifestations O
. O

Evaluation O
of O
PML B-NonOSE_AE
includes O
, O
but O
is O
not O
limited O
to O
, O
consultation O
with O
a O
neurologist O
, O
brain O
MRI O
, O
and O
lumbar O
puncture O
. O

Discontinue O
Rituxan O
and O
consider O
discontinuation O
or O
reduction O
of O
any O
concomitant O
chemotherapy O
or O
immunosuppressive O
therapy O
in O
patients O
who O
develop O
PML B-NonOSE_AE
. O

[ O
See O
Boxed O
Warning O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.5 O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TLS I-OSE_Labeled_AE
) O
Acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
, O
hyperkalemia B-NonOSE_AE
, O
hypocalcemia B-NonOSE_AE
, O
hyperuricemia B-NonOSE_AE
, O
or O
hyperphosphatemia B-NonOSE_AE
from O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
can O
occur O
within O
12-24 O
hours O
after O
the O
first O
infusion O
of O
Rituxan O
in O
patients O
with O
NHL B-Not_AE_Candidate
. O

A O
high B-Not_AE_Candidate
number I-Not_AE_Candidate
of I-Not_AE_Candidate
circulating I-Not_AE_Candidate
malignant I-Not_AE_Candidate
cells I-Not_AE_Candidate
( I-Not_AE_Candidate
> I-Not_AE_Candidate
= I-Not_AE_Candidate
2 I-Not_AE_Candidate
5 I-Not_AE_Candidate
, I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
) O
or O
high O
tumor B-Not_AE_Candidate
burden O
, O
confers O
a O
greater O
risk O
of O
TLS B-NonOSE_AE
. O

Administer O
aggressive O
intravenous O
hydration O
and O
anti-hyperuricemic O
therapy O
in O
patients O
at O
high O
risk O
for O
TLS B-NonOSE_AE
. O

Correct O
electrolyte B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
monitor O
renal O
function O
and O
fluid O
balance O
, O
and O
administer O
supportive O
care O
, O
including O
dialysis O
as O
indicated O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.8 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.6 O
Infections O
Serious O
, O
including O
fatal B-NonOSE_AE
, O
bacterial B-OSE_Labeled_AE
, O
fungal O
, O
and O
new O
or O
reactivated O
viral O
infections I-OSE_Labeled_AE
can O
occur O
during O
and O
following O
the O
completion O
of O
Rituxan-based O
therapy O
. O

Infections B-OSE_Labeled_AE
have O
been O
reported O
in O
some O
patients O
with O
prolonged O
hypogammaglobulinemia B-NonOSE_AE
( O
defined O
as O
hypogammaglobulinemia B-NonOSE_AE
> O
11 O
months O
after O
rituximab O
exposure O
) O
. O

New O
or O
reactivated O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
included O
cytomegalovirus B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
, O
parvovirus B-OSE_Labeled_AE
B I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
, O
varicella B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
, O
West B-OSE_Labeled_AE
Nile I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
, O
and O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
and O
C O
. O
Discontinue O
Rituxan O
for O
serious O
infections B-NonOSE_AE
and O
institute O
appropriate O
anti-infective O
therapy O
. O

[ O
See O
Adverse O
Reactions O
( O
6 O
, O
6.1 O
) O
] O
. O

5.7 O
Cardiovascular B-OSE_Labeled_AE
Discontinue O
infusions O
for O
serious O
or O
life-threatening O
cardiac B-NonOSE_AE
arrhythmias I-NonOSE_AE
. O

Perform O
cardiac O
monitoring O
during O
and O
after O
all O
infusions O
of O
Rituxan O
for O
patients O
who O
develop O
clinically O
significant O
arrhythmias B-NonOSE_AE
, O
or O
who O
have O
a O
history O
of O
arrhythmia B-Not_AE_Candidate
or O
angina B-Not_AE_Candidate
. O

[ O
See O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.8 O
Renal O
Severe O
, O
including O
fatal B-NonOSE_AE
, O
renal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
can O
occur O
after O
Rituxan O
administration O
in O
patients O
with O
NHL B-Not_AE_Candidate
. O

Renal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
has O
occurred O
in O
patients O
who O
experience O
tumor B-NonOSE_AE
lysis I-NonOSE_AE
syndrome I-NonOSE_AE
and O
in O
patients O
with O
NHL B-Not_AE_Candidate
administered O
concomitant O
cisplatin O
therapy O
during O
clinical O
trials O
. O

The O
combination O
of O
cisplatin O
and O
Rituxan O
is O
not O
an O
approved O
treatment O
regimen O
. O

Monitor O
closely O
for O
signs O
of O
renal B-NonOSE_AE
failure I-NonOSE_AE
and O
discontinue O
Rituxan O
in O
patients O
with O
a O
rising B-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
or O
oliguria B-NonOSE_AE
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

5.9 O
Bowel O
Obstruction O
and O
Perforation O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
bowel B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
and O
perforation O
, O
in O
some O
cases O
leading O
to O
death B-NonOSE_AE
, O
can O
occur O
in O
patients O
receiving O
Rituxan O
in O
combination O
with O
chemotherapy O
. O

In O
postmarketing O
reports O
, O
the O
mean O
time O
to O
documented O
gastrointestinal B-NonOSE_AE
perforation O
was O
6 O
( O
range O
1-77 O
) O
days O
in O
patients O
with O
NHL O
. O

Evaluate O
if B-Not_AE_Candidate
symptoms O
of O
obstruction I-NonOSE_AE
such O
as O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
or O
repeated O
vomiting B-NonOSE_AE
occur O
. O

[ O
See O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.10 O
Immunization O
The O
safety O
of O
immunization O
with O
live O
viral O
vaccines O
following O
Rituxan O
therapy O
has O
not O
been O
studied O
and O
vaccination O
with O
live O
virus O
vaccines O
is O
not O
recommended O
. O

For O
RA B-Not_AE_Candidate
patients O
, O
physicians O
should O
follow O
current O
immunization O
guidelines O
and O
administer O
non-live O
vaccines O
at O
least O
4 O
weeks O
prior O
to O
a O
course O
of O
Rituxan O
. O

The O
effect O
of O
Rituxan O
on O
immune O
responses O
was O
assessed O
in O
a O
randomized O
, O
controlled O
study O
in O
patients O
with O
RA B-Not_AE_Candidate
treated O
with O
Rituxan O
and O
methotrexate O
( O
MTX O
) O
compared O
to O
patients O
treated O
with O
MTX O
alone O
. O

A O
response O
to O
pneumococcal O
vaccination O
( O
a O
T-cell O
independent O
antigen O
) O
as O
measured O
by O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
titers I-OSE_Labeled_AE
to I-OSE_Labeled_AE
at I-OSE_Labeled_AE
least I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
of I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
serotypes I-OSE_Labeled_AE
was I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
in O
patients O
treated O
with O
Rituxan O
plus O
MTX O
as O
compared O
to O
patients O
treated O
with O
MTX O
alone O
( O
19 O
% O
vs O
. O
61 O
% O
) O
. O

A O
lower B-OSE_Labeled_AE
proportion I-OSE_Labeled_AE
of I-OSE_Labeled_AE
patients I-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
Rituxan I-OSE_Labeled_AE
plus I-OSE_Labeled_AE
MTX I-OSE_Labeled_AE
group I-OSE_Labeled_AE
developed I-OSE_Labeled_AE
detectable I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
keyhole I-OSE_Labeled_AE
limpet I-OSE_Labeled_AE
hemocyanin I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
( I-OSE_Labeled_AE
a I-OSE_Labeled_AE
novel I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
antigen I-OSE_Labeled_AE
) I-OSE_Labeled_AE
after I-OSE_Labeled_AE
vaccination I-OSE_Labeled_AE
compared O
to O
patients O
on O
MTX O
alone O
( O
47 O
% O
vs O
. O
93 O
% O
) O
. O

A O
positive O
response O
to O
tetanus O
toxoid O
vaccine O
( O
a O
T-cell O
dependent O
antigen O
with O
existing O
immunity O
) O
was O
similar O
in O
patients O
treated O
with O
Rituxan O
plus O
MTX O
compared O
to O
patients O
on O
MTX O
alone O
( O
39 O
% O
vs O
. O
42 O
% O
) O
. O

The O
proportion O
of O
patients O
maintaining O
a O
positive B-NonOSE_AE
Candida I-NonOSE_AE
skin I-NonOSE_AE
test I-NonOSE_AE
( O
to O
evaluate O
delayed O
type O
hypersensitivity B-NonOSE_AE
) O
was O
also O
similar O
( O
77 O
% O
of O
patients O
on O
Rituxan O
plus O
MTX O
vs O
. O
70 O
% O
of O
patients O
on O
MTX O
alone O
) O
. O

Most O
patients O
in O
the O
Rituxan-treated O
group O
had O
B B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
counts I-NonOSE_AE
below I-NonOSE_AE
the I-NonOSE_AE
lower I-NonOSE_AE
limit I-NonOSE_AE
of I-NonOSE_AE
normal I-NonOSE_AE
at O
the O
time O
of O
immunization O
. O

The O
clinical O
implications O
of O
these O
findings O
are O
not O
known O
. O

5.11 O
Laboratory O
Monitoring O
In O
patients O
with O
lymphoid B-Not_AE_Candidate
malignancies I-Not_AE_Candidate
, O
during O
treatment O
with O
Rituxan O
monotherapy O
, O
obtain O
complete O
blood O
counts O
( O
CBC O
) O
and O
platelet O
counts O
prior O
to O
each O
Rituxan O
course O
. O

During O
treatment O
with O
Rituxan O
and O
chemotherapy O
, O
obtain O
CBC O
and O
platelet O
counts O
at O
weekly O
to O
monthly O
intervals O
and O
more O
frequently O
in O
patients O
who O
develop O
cytopenias B-NonOSE_AE
[ O
See O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
patients O
with O
RA B-Not_AE_Candidate
, O
GPA B-Not_AE_Candidate
or O
MPA B-Not_AE_Candidate
, O
obtain O
CBC O
and O
platelet O
counts O
at O
two O
to O
four O
month O
intervals O
during O
Rituxan O
therapy O
. O

The O
duration O
of O
cytopenias B-NonOSE_AE
caused O
by O
Rituxan O
can O
extend O
months O
beyond O
the O
treatment O
period O
. O

5.12 O
Concomitant O
Use O
with O
Biologic O
Agents O
and O
DMARDS O
other O
than O
Methotrexate O
in O
RA O
, O
GPA O
and O
MPA O
Limited O
data O
are O
available O
on O
the O
safety O
of O
the O
use O
of O
biologic O
agents O
or O
DMARDs O
other O
than O
methotrexate O
in O
RA B-Not_AE_Candidate
patients O
exhibiting O
peripheral O
B B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
depletion I-NonOSE_AE
following O
treatment O
with O
rituximab O
. O

Observe O
patients O
closely O
for O
signs O
of O
infection B-NonOSE_AE
if O
biologic O
agents O
and/or O
DMARDs O
are O
used O
concomitantly O
. O

Use O
of O
concomitant O
immunosuppressants O
other O
than O
corticosteroids O
has O
not O
been O
studied O
in O
GPA B-Not_AE_Candidate
or O
MPA B-Not_AE_Candidate
patients O
exhibiting O
peripheral O
B B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
depletion I-NonOSE_AE
following O
treatment O
with O
Rituxan O
. O

5.13 O
Use O
in O
RA O
Patients O
Who O
Have O
Not O
Had O
Prior O
Inadequate O
Response O
to O
Tumor O
Necrosis O
Factor O
( O
TNF O
) O
Antagonists O
While O
the O
efficacy O
of O
Rituxan O
was O
supported O
in O
four O
controlled O
trials O
in O
patients O
with O
RA B-Not_AE_Candidate
with O
prior O
inadequate O
responses O
to O
non-biologic O
DMARDs O
, O
and O
in O
a O
controlled O
trial O
in O
MTX-naive O
patients O
, O
a O
favorable O
risk-benefit O
relationship O
has O
not O
been O
established O
in O
these O
populations O
. O

The O
use O
of O
Rituxan O
in O
patients O
with O
RA B-Not_AE_Candidate
who O
have O
not O
had O
prior O
inadequate O
response O
to O
one O
or O
more O
TNF O
antagonists O
is O
not O
recommended O
[ O
See O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

5.14 O
Retreatment O
in O
Patients O
with O
Granulomatosis O
with O
Polyangiitis O
( O
GPA O
) O
( O
Wegener O
's O
Granulomatosis O
) O
and O
Microscopic O
Polyangiitis O
( O
MPA O
) O
Limited O
data O
are O
available O
on O
the O
safety O
and O
efficacy O
of O
subsequent O
courses O
of O
Rituxan O
in O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
. O

The O
safety O
and O
efficacy O
of O
retreatment O
with O
Rituxan O
have O
not O
been O
established O
[ O
See O
Dosage O
and O
Administration O
( O
2.6 O
) O
, O
Adverse O
Reactions O
( O
6.3 O
) O
, O
and O
Clinical O
Studies O
( O
14.7 O
) O
] O
. O

